Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: A retrospective longitudinal study

Cancer Letters

Volumn 263, Issue 1, 2008, Pages 122-129

  Nicolini, A ^a   Carpi, A ^a   Ferrari, P ^a   Rossi, G ^b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Breast cancer; Immunotherapy; Tumour markers

Indexed keywords

ANTIESTROGEN; BETA INTERFERON; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; INTERLEUKIN 2; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TISSUE POLYPEPTIDE ANTIGEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONE DEPENDENCE; HUMAN; LONGITUDINAL STUDY; MASTECTOMY; MENOPAUSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE POLYPEPTIDE ANTIGEN;

EID: 41049116496     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.12.020     Document Type: Article

References (26)

1. Nicolini A., and Carpi A. Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol. 21 4 (2000) 235-248
2. Nicolini A., Carpi A., and Ferrari P. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol. 24 6 (2003) 275-280
3. Nicolini A., Anselmi L., Michelassi C., et al. Prolonged survival by'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br. J. Cancer 76 8 (1997) 1106-1111
4. Nicolini A., and Carpi A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed. Pharmacother. 59 5 (2005) 253-263
5. Nicolini A., Carpi A., and Rossi G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J. Immunother. 28 3 (2005) 276-279
6. Nicolini A., Carpi A., and Rossi G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. Cancer Lett. Jan 8 (2007) Epub ahead of print
7. Lonning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J. Clin. Oncol. 18 11 (2000) 2234-2244
8. Nicolini A., Ferrari P., Sagripanti A., and Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br. J. Cancer 79 9-10 (1999) 1443-1447
9. Nicolini A., Carpi A., Ferrari P., et al. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br. J. Cancer 83 11 (2000) 1412-1417
10. Soletormos G., Schioler V., Nielsen D., et al. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin. Chem. 39 10 (1993) 2077-2083
11. Pronk L.C., Stoter G., van Putten W.L., et al. The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 123 2 (1997) 128-132
12. Nicolini A., Tartarelli G., Carpi A., Metelli M.R., Ferrari P., Anselmi L., Conte M., Berti P., and Miccoli P. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 6 (2006) 269
13. Bast Jr. R.C., Ravdin P., Hayes D.F., et al. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19 6 (2001) 1865-1878
14. Nicolini A., Carpi A., and Tarro G. Biomolecular markers of breast cancer. Front. Biosci. 11 (2006) 1818-1843
15. Seregni E., Coli A., and Mazzucca N. Italian Group RIA-IRMA Test, Italian Association of Nuclear Medicine. Circulating tumour markers in breast cancer. Eur. J. Nucl. Med. Mol. Imaging 31 Suppl. 1 (2004) S15-S22
16. Nicolini A., Carpi A., Michelassi C., et al. Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed. Pharmacother. 57 10 (2003) 452-459
17. Molina R., Barak V., Van Dalen A., et al. Tumor markers in breast cancer-Recommendations. Tumor Biol. 26 (2005) 281-293
18. Barak V., Nisman B., Roisman I., et al. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J. Tumor Marker Oncol. 12 (1997) 17-26
19. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16 (1998) 3439-3460
20. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol. 18 (2000) 3748-3757
21. S.K.L. Chia, C. Speers, A. Kang, et al., The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort, in: Proceedings ASCO 2003, p. 89.
22. Iwase H., Kobayashi S., Itoh Y., et al. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res. Treat. 33 (1994) 83-88
23. Soletormos G., Nielsen D., Schioler V., et al. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur. J. Cancer 40 4 (2004) 481-486
24. Van Dalen A., Heering K.J., Barak V., et al. Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes. Breast 5 (1996) 82-88
25. Van Dalen A., Barak V., Cremaschi A., et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int. J. Biol. Markers 13 1 (1998) 10-15 Jan-Mar
26. Jager W., Merkle E., and Lang N. Increasing serum tumor markers as decision criteria for hormone-therapy of metastatic breast cancer. Tumor Biol. 12 (1994) 60-66